Most Recent
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.
A Western Australian couple has sued fertility services provider Monash IVF after the company implanted a woman with a different embryo than the one they had donated.
Pharmacor has accused AstraZeneca of launching a royal commission into emails with its lawyers as AstraZeneca opposes the generic drug maker's bid to amend its pleading in a patent case over diabetes drug Forxiga.
US drug maker Pfizer has been hit with a class action alleging it knew or ought to have known about the increased risk that patients who used its injectable contraceptive Depo-Provera could develop brain tumors.
A judge has said women who donated eggs to their same-sex partners and were removed from a class action over IVF rebates could potentially revive their claims, but the lead applicant has not yet indicated whether she will pursue this path.
Pathology services provider Australian Clinical Labs has been hit with a class action over a 2022 data breach that compromised the sensitive personal information of 223,000 customers of its Medlab business, including tests for fertility and STDs.
Melbourne-based biopharma Telix has filed a lawsuit against Purdue Research Foundation seeking to invalidate its patent for blockbuster prostate cancer treatment Pluvicto.
A judge hearing a class action against J&J over allegedly ineffective cold medications has questioned the merits of soft class closure in large consumer cases where participation is likely be low, just days after another judge raised similar concerns in a case against Toyota.
AstraZeneca can inspect Pharmacor's emails to verify its claim that the merits of its challenge to a patent extension for blockbuster diabetes drug Forxiga were not appreciated at an earlier time, with a judge finding Pharmacor had waived privilege.